论文部分内容阅读
作者对105例表浅膀胱肿瘤腔内BCG治疗的相关病理变化及临床疗效进行评估。预防组60例,为多发乳头状瘤行经尿道电切除手术(TURBT)后患者,治疗组45例,为原位癌和/或粘膜下微浸润者,预防组中28例及治疗组中17例原先采用腔内化疗无效。全部病例采用75mgPasteurBCG行膀胱内灌注1次/周×6,若肿瘤消失改维持治疗,即第一年1次
The author of 105 cases of superficial bladder cancer intracavitary BCG treatment of pathological changes and clinical evaluation. Prevention group of 60 patients with multiple papilloma underwent transurethral resection (TURBT) patients, the treatment group 45 cases, in situ carcinoma and / or submucosal microinvasive were 28 cases in the prevention group and 17 cases in the treatment group The original use of intracavitary chemotherapy is invalid. All patients with intraperitoneal injection of 75mg PasteurBCG perfusion 1 times / week × 6, if the tumor disappeared to maintain treatment, that is, the first year of 1